Predicting acute diarrhoea in rectal cancer chemoradiotherapy: Secondary analysis of the phase III ARISTOTLE trial.
No Thumbnail Available
All Authors
Zhang, Y.
Brand, D.
Shen, Z.
Simard, M.
Hindocha, S.
Chohan, O.
Lopes, A.
Begum, R.
West, N.
Appelt, A.
LTHT Author
Appelt, Ane
LTHT Department
Oncology
Leeds Cancer Centre
Medical Physics & Engineering
Leeds Cancer Centre
Medical Physics & Engineering
Non Medic
Physicist
Publication Date
2025
Item Type
Journal Article
Clinical Trial
Multicenter Study
Randomised Controlled Trial
Clinical Trial
Multicenter Study
Randomised Controlled Trial
Language
Subject
Subject Headings
Abstract
BACKGROUND: Neoadjuvant chemoradiotherapy is a standard treatment for locally advanced rectal cancer, but acute diarrhoea remains a significant side effect, affecting the completion of chemoradiotherapy treatment.
PURPOSE: This study aimed to predict acute diarrhoea after neoadjuvant chemoradiotherapy for rectal cancer and further develop a strategic tool to individualise rectal cancer treatment.
MATERIALS AND METHODS: The ARISTOTLE trial is a phase III trial comparing capecitabine chemo-radiotherapy (CRT) versus capecitabine-irinotecan CRT as a pre-operative treatment for locally advanced rectal cancer. We included 589 trial patients across 73 institutions. The volume of the AI-segmented small bowel receiving at least 10 Gy (V10Gy) was used alongside the treatment arm, patient age, and performance status in a logistic regression model to predict a more than 2-grade increase in acute diarrhoea toxicity from baseline (DELTAG >= 2). Finally, based on the prediction, we identified a sub-cohort of patients for whom a viable dose decrease would result in a reduction of toxicity, and conversely, we also identified individuals for whom adding irinotecan may not cause toxicity.
RESULTS: The average mean receiver operating characteristic curve (AUROC) for predicting DELTAG >= 2 is 0.71 [95 % CI 0.58-0.82] on the independent test dataset. Based on the prediction, we identified 71 patients (14 %) who could potentially benefit from irinotecan addition without a dose decrease to maintain DELTAG < 2, and 77 patients (15 %) who could potentially benefit from irinotecan addition but need a dose decrease to maintain DELTAG < 2.
CONCLUSION: The multi-institutional cohort of 73 centres strengthens the reliability of these findings, demonstrating the model's potential as a strategic tool to individualise rectal cancer treatment while mitigating severe diarrhoea.
Journal
Radiotherapy & Oncology